Cargando…

Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients

OBJECTIVE: To evaluate the change in adjuvant therapeutic decision in a cohort of young women with breast cancer discussed by a multidisciplinary team, before and after EndoPredict testing. PATIENTS AND METHODS: 99 premenopausal women with hormone receptor-positive, HER2-negative, T1-T2, and N0-N1 b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villarreal-Garza, Cynthia, Lopez-Martinez, Edna Anakarenn, Deneken-Hernandez, Zuratzi, Maffuz-Aziz, Antonio, Muñoz-Lozano, Jose Felipe, Barragan-Carrillo, Regina, Ramos-Elias, Pier, Moreno, Brizio, Diaz-Perez, Hector, Peña-Curiel, Omar, Curiel-Valdez, Jose de Jesus, Bautista-Piña, Veronica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065749/ https://www.ncbi.nlm.nih.gov/pubmed/32160201 http://dx.doi.org/10.1371/journal.pone.0228884

Ejemplares similares

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions
por: Müller, Berit Maria, et al.
Publicado: (2013)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort
por: Somashekhar, S. P., et al.
Publicado: (2020)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections
por: Müller, Berit Maria, et al.
Publicado: (2012)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
por: Denkert, Carsten, et al.
Publicado: (2012)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay
por: Soliman, Hatem, et al.
Publicado: (2019)

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
por: Martin, Miguel, et al.
Publicado: (2014)

Association between Maternal and Toddler Appetitive Traits in a Mexican Population
por: González-Toribio, Jocelyn, et al.
Publicado: (2023)

Phyllodes Tumor of the Breast: 307 Treated Cases, the Largest Mexican Experience at a Single Breast Disease Institution
por: Ruvalcaba-Limón, Eva, et al.
Publicado: (2016)

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1
por: Ettl, Johannes, et al.
Publicado: (2017)

Intergenerational transmission of appetite: Associations between mother-child dyads in a Mexican population
por: Hunot-Alexander, Claudia, et al.
Publicado: (2022)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Characterization of triple negative breast cancer gene expression profiles in Mexican patients
por: Ortiz Valdez, Eric, et al.
Publicado: (2022)

Validity and Reliability of the Baby and Child Eating Behavior Questionnaire, Toddler Version (BEBQ-Mex and CEBQ-T-Mex) in a Low Sociodemographic Sample Recruited in a Mexican Hospital
por: Hunot-Alexander, Claudia, et al.
Publicado: (2021)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Association study in Mexican patients with thyrotoxic hypokalemic periodic paralysis
por: Bautista-Medina, Mario Arturo, et al.
Publicado: (2020)

Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Application of Biotechnological Techniques Aimed to Obtain Bioactive Compounds from Food Industry By-Products
por: Curiel, Jose Antonio
Publicado: (2021)

Locally advanced breast cancer in young women in Latin America
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2019)

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
por: Lambertini, Matteo, et al.
Publicado: (2019)

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
por: Kronenwett, Ralf, et al.
Publicado: (2012)

Young Women with Breast Cancer in Resource-Limited Settings: What We Know and What We Need to Do Better
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
por: Martin, Miguel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s3mtpeql7gpgenbp8nib0ar817